R&D | Cutting-edge science and innovative research

News

ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data

Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.

News

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

A study of RevMed's Rasonque with Tango's vopimetostat has raised hopes of a new combination therapy for aggressive pancreatic cancer.

News

US Treasury proposes curbs on Chinese biotech deals

China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.

News

ESMO26: Moderna, MSD reveal cancer jab data early after leak

Moderna and MSD shared the results for their melanoma cancer vaccine trial, ahead of a presentation at ESMO tomorrow, after a data breach.

News

Clinical trial setup times fall sharply in UK

Reforms to the regulatory framework for clinical research in the UK are starting to deliver, with delivery times down 35%, according to new data.

News

GSK partners LifeMine on fungi-derived medicines

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underex

Digital

AI tool helps detect leprosy using pictures

Ann Aerts, head of the Novartis Foundation, tells us about AI4Leprosy, a diagnostic assistant researchers developed that helps healthcare workers detect leprosy with over 90% accuracy using

News

With rivals threatening, Argenx scores key myasthenia gravis...

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia gravis (gMG), but is already looking to defend its

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data

Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.

News

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

A study of RevMed's Rasonque with Tango's vopimetostat has raised hopes of a new combination therapy for aggressive pancreatic cancer.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Wooden pawns on top of wooden block named BOARD

Changing Faces: Board of Director and Advisory Board hires, ...

September’s boardroom moves brought seasoned pharma executives, investors, and scientific leaders into new governance and advisory roles across the life sciences sector.

R&D

Digital box and pills, supply chain concept for pharma

From reactive to predictive: How data is redefining pharma l...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight.

R&D

Depressed woman looks out rain spattered window in city

Removing barriers in treatment-resistant depression

pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Boosting biotech in Basel – with Valentina Francia

pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.